| 胡梦奕,王永生,屠小龙,张婷素.中药联合阿帕替尼治疗晚期胃癌疗效与安全性的Meta分析[J].浙江中西医结合杂志,2022,32(3): |
| 中药联合阿帕替尼治疗晚期胃癌疗效与安全性的Meta分析 |
| Meta-analysis of Efficacy and Safety of Traditional Chinese Medicine Combined with Apatinibin Treatment of Advanced Gastric Cancer |
| 投稿时间：2021-10-12 修订日期：2021-11-18 |
| DOI： |
| 中文关键词: 中药 阿帕替尼 晚期胃癌 随机对照试验 Meta分析 |
| 英文关键词:traditional Chinese medicine apatinib advanced gastric cancer randomized controlled trials Meta-analysis |
| 基金项目: |
|
| 摘要点击次数: 650 |
| 全文下载次数: 18 |
| 中文摘要: |
| 目的：评价中药联合阿帕替尼治疗晚期胃癌的疗效及安全性。方法：检索中国知网(CNKI)、万方、维普(VIP)、中国生物医学文献(CBM)、Pubmed等数据库中有关中药联合阿帕替尼治疗晚期胃癌的临床随机对照试验(RCTs),按照纳入排除标准筛选文献、提取资料并评价文献质量,运用RevMan 5.3软件进行分析。结果：最终纳入11篇文献,共计656例患者,其中试验组329例,对照组327例。结果显示中药联合阿帕替尼治疗晚期胃癌在客观缓解率、疾病控制率、提高卡氏(KPS)评分、减少不良反应发生等方面均优于对照组(P＜0.01,P＜0.05)。在免疫功能方面,中药联合阿帕替尼可提高CD3+、CD4+和CD4+/CD8+水平,且优于对照组(P＜0.01)；而对于CD8+水平两组间比较无统计学意义(P＞0.05)。结论：中药联合阿帕替尼治疗晚期胃癌具有显著疗效,并能减少不良反应的发生。但因中药的特殊性以及纳入的研究质量较低,仍需开展更多高质量的临床RCTs予以进一步验证。 |
| 英文摘要: |
| Objective: To evaluate the efficacy and safety of traditional Chinese medicine(TCM) combined with apatinib on treating advanced gastric cancer. Methods: The clinical randomized controlled trials (RCTs) of TCM combined with apatinib in the treatment of advanced gastric cancer were searched in CNKI, Wanfang, VIP, CBM, PubMed and other databases. According to the inclusion and exclusion criteria, the literature was screened, the data were extracted and the literature quality was evaluated.The Revman 5.3 software was used to analyze the data included. Results: A total of 11 RCTs were included, 656 cases of advanced gastric cancer in which 329 cases in TCM combined with apatinib, and 327 cases in apatinib control group included. The results showed that TCM combined with apatinib was superior to the control group in objective remission rate, disease control rate, improving KPS score and reducing adverse reactions(P＜0.01, P＜0.05). In terms of immune function, TCM combined with apatinib could increase the levels of CD3+, CD4+ and CD4+/CD8+, which was better than that in the control group (P＜0.01), but there was no significant difference in the level of CD8+ between the two groups (P＞0.05). Conclusion: TCM combined with apatinib is effective in the treatment of advanced gastric cancer and can reduce the incidence of adverse reactions. However, due to the particularity of TCM and the low quality of the included studies, more high-quality clinical RCTs need to be carried out for further verification. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
